ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 76 citations in OpenAlex.
- Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.British journal of haematology · 2012Trial
- A pan-cancer atlas of therapeutic T cell targets.bioRxiv : the preprint server for biology · 2025Article
- MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation.Science advances · 2025Article
- Comparative responses to demethylating therapy in animal models of osteosarcoma.Research square · 2024Article
- The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?Cancers · 2023Review
- Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells.Frontiers in pharmacology · 2023Article
- Review
- MAGEA4 Coated Extracellular Vesicles Are Stable and Can Be Assembled In Vitro.International journal of molecular sciences · 2021Article
- Targeting the epigenetic regulation of antitumour immunity.Nature reviews. Drug discovery · 2020Review
- Article
- Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.Cancers · 2020Review
- Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.Cancer immunology research · 2019Review
- Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.Current oncology reports · 2019Review
- Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets.Journal of ovarian research · 2019Review
- Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma CellsFrontiers in immunology · 2018Article
- Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.International journal of molecular sciences · 2017Article
- Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Current drug targets · 2017Review
- DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Cancer immunology, immunotherapy : CII · 2016Article
Corrections and comments
- Commented on by
- Erratum issuedDosage error in article text
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
purposePatients with Hodgkin lymphoma (HL) relapsing after hematopoietic stem cell transplant have limited options for long-term cure. We have shown that infused cytotoxic T cells (CTL) targeting Epstein Barr virus (EBV)-derived proteins induced complete remissions in EBV(+) HL patients. A limitation of this approach is that up to 70% of relapsed HL tumors are EBV-negative. For these patients, an alternative is to target the cancer/testis antigen MAGE-A4 present in EBV antigen-negative HL tumors. Furthermore, epigenetic modification by clinically available demethylating agents can enhance MAGE-A4 expression in previously MAGE-negative tumors. EXPERIMENTAL
designWe explored the feasibility of combining adoptive T cell therapy with epigenetic modification of tumor antigen expression. We further characterized MAGE-A4-specific T-cell phenotype and function, and examined the effects of the epigenetic modifying drug decitabine on these T cells.
resultsCytotoxic T cells were generated specifically recognizing MAGE-A4 expressed by autologous HL targets and tumor cell lines. Decitabine-previously shown to increase tumor antigen expression in HL-did not compromise MAGE-A4-specific T-cell phenotype and function. In patients treated with decitabine, expanded MAGE-A4-specific T cells had a broader antitumor T cell repertoire, consistent with increased antigen stimulation in vivo.
conclusionsAdoptive transfer of MAGE-A4-specific T cells, combined with epigenetic modifying drugs to increase expression of the protein, may improve treatment of relapsed HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.